Next Article in Journal
The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism
Next Article in Special Issue
Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740
Previous Article in Journal
Untargeted Metabolic Profiling of Extracellular Vesicles of SARS-CoV-2-Infected Patients Shows Presence of Potent Anti-Inflammatory Metabolites
Previous Article in Special Issue
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
 
 
Review

Treatment of Sjögren’s Syndrome with Mesenchymal Stem Cells: A Systematic Review

1
UFR d’Odontologie, University of Western Brittany, 29200 Brest, France
2
CHU de Brest, 29609 Brest, France
3
Inserm, LBAI, University of Western Brittany, UMR1227, 29609 Brest, France
*
Author to whom correspondence should be addressed.
Academic Editor: Biji Theyilamannil Kurien
Int. J. Mol. Sci. 2021, 22(19), 10474; https://doi.org/10.3390/ijms221910474
Received: 21 July 2021 / Revised: 23 September 2021 / Accepted: 23 September 2021 / Published: 28 September 2021
(This article belongs to the Special Issue Lymphocyte Signalling and Function in Systemic Autoimmune Diseases)
Mesenchymal stem cells (MSCs) are ubiquitous in the human body. Mesenchymal stem cells were initially isolated from bone marrow and later from other organs such as fatty tissues, umbilical cords, and gingiva. Their secretory capacities give them interesting immunomodulatory properties in cell therapy. Some studies have explored the use of MSCs to treat Sjögren’s syndrome (SS), a chronic inflammatory autoimmune disease that mainly affects exocrine glands, including salivary and lacrimal glands, although current treatments are only palliative. This systematic review summarizes the current data about the application of MSCs in SS. Reports show improvements in salivary secretions and a decrease in lymphocytic infiltration in salivary glands in patients and mice with SS after intravenous or infra-peritoneal injections of MSCs. MSC injections led to a decrease in inflammatory cytokines and an increase in anti-inflammatory cytokines. However, the intrinsic mechanism of action of these MSCs currently remains unknown. View Full-Text
Keywords: mesenchymal stem cells; Sjögren’s syndrome; oral sicca; xerostomia mesenchymal stem cells; Sjögren’s syndrome; oral sicca; xerostomia
Show Figures

Figure 1

MDPI and ACS Style

Chihaby, N.; Orliaguet, M.; Le Pottier, L.; Pers, J.-O.; Boisramé, S. Treatment of Sjögren’s Syndrome with Mesenchymal Stem Cells: A Systematic Review. Int. J. Mol. Sci. 2021, 22, 10474. https://doi.org/10.3390/ijms221910474

AMA Style

Chihaby N, Orliaguet M, Le Pottier L, Pers J-O, Boisramé S. Treatment of Sjögren’s Syndrome with Mesenchymal Stem Cells: A Systematic Review. International Journal of Molecular Sciences. 2021; 22(19):10474. https://doi.org/10.3390/ijms221910474

Chicago/Turabian Style

Chihaby, Najwa, Marie Orliaguet, Laëtitia Le Pottier, Jacques-Olivier Pers, and Sylvie Boisramé. 2021. "Treatment of Sjögren’s Syndrome with Mesenchymal Stem Cells: A Systematic Review" International Journal of Molecular Sciences 22, no. 19: 10474. https://doi.org/10.3390/ijms221910474

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop